OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $146M, compared with -$77K a year earlier. Trailing-twelve-month financing cash flow was $146.24M. Over 3 fiscal years it compounded at -81.7% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $146M or moves back toward the trailing-twelve-month quarterly average of $36.56M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 163K USD
- Year-over-year change
- -99.9%
- 4-year CAGR
- -81.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 163K | -99.9% |
| FY2024 | 2024-12-31 | 116.13M | +118.6% |
| FY2023 | 2023-12-31 | 53.13M | +100.7% |
| FY2022 | 2022-12-31 | 26.47M | -80.0% |
| FY2021 | 2021-12-31 | 132.41M | — |
Financing Cash Flow vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's LTM Mar 2026 financing cash flow of $146.24M is the 2nd largest of the 4 companies compared; the peer median is $217K.
- Its year-over-year change of +21.9% is the 2nd highest of 4, against a peer median of -104.7%.
- Over three fiscal years its annual growth of -81.7% compares with a peer median of +619.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $674.37M | -9094.6% | +619.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $146.24M | +21.9% | -81.7% | — |
| LTM Mar 2026 | $118.65M | +258.7% | — | 221.8% | |
| LTM Jun 2026 | $217K | -104.7% | — | 0.6% | |
| Peer median (excluding OKUR) | $217K | -104.7% | +619.6% | 111.2% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 48K | 199K | 4.53M | 11.63M |
| Change in Working Capital | (2.8M) | 2.12M | 6K | (3.95M) | (4.78M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 1.71M | (5.93M) | (4.55M) |
| Other Working Capital | (2.8M) | 2.12M | (1.71M) | 1.98M | (235K) |
| Other Non-Cash Items | 4.54M | 0 | 0 | 316K | 6K |
| Operating Cash Flow | (37.98M) | (26.95M) | (34.55M) | (51.12M) | (51.83M) |
| Capital Expenditures | (198K) | (1.13M) | (246K) | (52K) | (46K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (31.41M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.23M | 44.1M | 0 | 15.93M | 0 |
| Other Investing Activities | 0 | (44.1M) | 0 | 0 | 0 |
| Investing Cash Flow | (23.38M) | (1.13M) | (246K) | 15.87M | (46K) |
| Debt Repayment | 0 | 0 | 0 | 6M | 0 |
| Common Stock Issued | 132.41M | 340K | 65K | 58.91M | 203K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.38M) | (723K) | 51.22M | (40K) |
| Financing Cash Flow | 132.41M | 26.47M | 53.13M | 116.13M | 163K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.05M | (1.62M) | 18.33M | 80.89M | (51.71M) |
| Free Cash Flow | (38.18M) | (28.09M) | (34.79M) | (51.17M) | (51.87M) |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.